

Celicia M Serenata

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1399313/publications.pdf>

Version: 2024-02-01

20
papers

860
citations

933264

10
h-index

839398

18
g-index

21
all docs

21
docs citations

21
times ranked

1079
citing authors

#	ARTICLE	IF	CITATIONS
1	Tracking adverse drug reactions and medication errors in the Central Chronic Medicine Dispensing and Distribution (CCMDD) programme in South Africa. <i>Southern African Journal of HIV Medicine</i> , 2022, 23, .	0.3	1
2	High individual pain variability in people living with HIV: A graphical analysis. <i>European Journal of Pain</i> , 2021, 25, 160-170.	1.4	0
3	Unexpected interactions between dolutegravir and folate: randomized trial evidence from South Africa. <i>Aids</i> , 2021, 35, 205-211.	1.0	11
4	Participants on Dolutegravir Resuppress Human Immunodeficiency Virus RNA After Virologic Failure: Updated Data from the ADVANCE Trial. <i>Clinical Infectious Diseases</i> , 2021, 73, e1008-e1010.	2.9	15
5	Implications of weight gain with newer anti-retrovirals: 10-year predictions of cardiovascular disease and diabetes. <i>Aids</i> , 2021, 35, 1657-1665.	1.0	40
6	The potential role of long-acting injectable cabotegravir+rilpivirine in the treatment of HIV in sub-Saharan Africa: a modelling analysis. <i>The Lancet Global Health</i> , 2021, 9, e620-e627.	2.9	31
7	The predicted risk of adverse pregnancy outcomes as a result of treatment-associated obesity in a hypothetical population receiving tenofovir alafenamide/emtricitabine/dolutegravir, tenofovir disoproxil fumarate/emtricitabine/dolutegravir or tenofovir disoproxil fumarate/emtricitabine/efavirenz. <i>Aids</i> , 2021, 35, S117-S125.	1.0	12
8	Patterns of Immune Activation in HIV and Non HIV Subjects and Its Relation to Cardiovascular Disease Risk. <i>Frontiers in Immunology</i> , 2021, 12, 647805.	2.2	8
9	Impact of long-acting therapies on the global HIV epidemic. <i>Aids</i> , 2021, 35, S137-S143.	1.0	16
10	Weight gain stopping/switch rules for antiretroviral clinical trials. <i>Aids</i> , 2021, 35, S183-S188.	1.0	15
11	What we have learned from antiretroviral treatment optimization efforts over the last 5 years?. <i>Aids</i> , 2021, 35, S113-S115.	1.0	2
12	Cost and cost-effectiveness of dolutegravir-based antiretroviral regimens: an economic evaluation of a clinical trial. <i>Aids</i> , 2021, 35, S173-S182.	1.0	5
13	Time to rethink endpoints for new clinical trials of antiretrovirals? Long-term re-suppression of HIV RNA with integrase inhibitors. <i>Aids</i> , 2020, 34, 321-324.	1.0	4
14	Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial. <i>Lancet HIV</i> , 2020, 7, e666-e676.	2.1	145
15	Phase 3 trials of new antiretrovirals are not representative of the global HIV epidemic. <i>Journal of Virus Eradication</i> , 2020, 6, 70-73.	0.3	20
16	Reduced efficacy of HIV-1 integrase inhibitors in patients with drug resistance mutations in reverse transcriptase. <i>Nature Communications</i> , 2020, 11, 5922.	5.8	55
17	Phase 3 trials of new antiretrovirals are not representative of the global HIV epidemic. <i>Journal of Virus Eradication</i> , 2020, 6, 70-73.	0.3	4
18	Dolutegravir plus Two Different Prodrugs of Tenofovir to Treat HIV. <i>New England Journal of Medicine</i> , 2019, 381, 803-815.	13.9	447

#	ARTICLE	IF	CITATIONS
19	Low-dose ritonavir-boosted darunavir once daily versus ritonavir-boosted lopinavir for participants with less than 50 HIV RNA copies per mL (WRHI 052): a randomised, open-label, phase 3, non-inferiority trial. <i>Lancet HIV</i> , 2019, 6, e428-e437.	2.1	14
20	Inclusion of pregnant women in antiretroviral drug research: what is needed to move forwards?. <i>Journal of the International AIDS Society</i> , 2019, 22, e25372.	1.2	15